Navigation Links
Joslin researchers increase understanding of genetic risk factor for type 1 diabetes
Date:11/28/2012

mouse model developed by Dr. Kissler's graduate student and co-author, Peilin Zheng. Using a technology that combines RNA interference, a method to silence gene expresson, with lentiviral transgenesis, a method to genetically modify animals, the scientists can manipulate gene activity in the most widely used mouse model for type 1 diabetes, the nonobese diabetic mouse (NOD). In this study, the researchers were able to easily turn off and on the PTPN22 gene in the NOD mouse. "We are the first to use this approach in the NOD mouse model," says Dr. Kissler. "It provides a very powerful way to study the contribution of PTPN22 to disease."

When PTPN22 was turned off in mice, mimicking a loss-of-function mutation, the researchers observed an increase in regulatory T cells and a decreased risk of autoimmune diabetes. "This is the first study conducted on the diabetic mouse model that supports the LYP gain-of-function hypothesis," says Dr. Kissler. "Our work should help to resolve the controversy."

By providing additional data that suggests the potential therapeutic value of PTPN22 manipulation, the study may further the development of new therapeutic options that inhibit LYP to reduce or prevent autoimmunity. "Our goal is to treat autoimmunity. Inhibiting LYP in patients may increase regulatory immune cells and could confer protection against autoimmunity, but it remains to be tested if our promising findings in this mouse model are reflected in humans," says Dr. Kissler.

The Joslin scientists are following up on this study to deepen understanding of how inhibiting PTPN22 affects T and B cells.


'/>"/>

Contact: Jeffrey Bright
jeffrey.bright@joslin.harvard.edu
617-309-1957
Joslin Diabetes Center
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Joslin researchers gain new understanding of diabetes and kidney disease
2. Fracking in Michigan: U-M researchers study potential impact on health, environment, economy
3. NREL researchers use imaging technologies to solve puzzle of plant architecture
4. NIH-funded researchers show possible trigger for MS nerve damage
5. Temple-Penn researchers identify calcium accelerator to keep cell power supply going
6. Researchers detail the migrations of the wood wasp Sirex noctilio
7. Researchers identify a simple way to precipitate phosphorus from the wastewater of a pulp mill
8. Researchers decode birch tree genome sequence for the first time
9. Researchers develop guidebook for promoting healthy lifestyles among Hispanic populations
10. Researchers study links between conflict and fisheries in East Africa
11. A class of RNA molecules protects germ cells from damage, Penn vet researchers show
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Joslin researchers increase understanding of genetic risk factor for type 1 diabetes
(Date:7/13/2015)... 13, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced sampling of ClearPad ® ... integration (TDDI) product targeting smartphones and tablets. This ... Synaptics , best-in-class touch controller IP and ... developed in the company,s Japan Design Center. TDDI ...
(Date:7/9/2015)... Calif. , July 9, 2015  Unchained ... today announcing its acquisition of Avid Nano. Avid ... light scattering (DLS) systems.    Also ... smallest, fastest and easiest to use protein sizing ... that measures a protein,s hydrodynamic size, size distribution, ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. (NASDAQ: ... diagnostics, today announced the launch of a study ... Precision Cancer Monitoring℠ (PCM) technology for predicting response ... or a combination of the novel immunotherapy agents ... a PD-1 inhibitor. The 50-patient study will be ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... greenhouse-gas emissions in comparison to fossil fuels. In the ... highlight a new study that factors in environmental costs ... short. The authors urge governments to be far more ... are more environmentally friendly than fossil fuels., Because fossil ...
... - The crystal structure of a molecule from a primitive ... more about the evolution of life from the simple to ... fungus protein bound to an RNA molecule, scientists from Purdue ... able to visualize how life progressed from an early self-replicating ...
... - Investigators at the University of Alabama at,Birmingham ... a,chemical ,messenger, leading to autoimmune disorders like rheumatoid,arthritis ... occurring chemical interleukin 17,(IL-17), an immunity protein. ... in autoimmune and,inflammatory responses, aside from its commonly ...
Cached Biology News:Scientists find missing evolutionary link using tiny fungus crystal 2Protein's new role discovered in autoimmune disease 2
(Date:7/29/2015)... Inc. (NYSE: BIOA ) today announced that ... resigned.  The Company has hired Andrew Ashworth , ... 2014, as full time interim CFO and has launched ... Andy Ashworth began his employment today, to overlap ... was the Company,s CFO from September 2011 to December ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... supplier, announces the launch of their 2nd generation cell therapy POD® design. The ... CT, but it also represents a new POD® design. , “G-CON first ...
(Date:7/29/2015)... CHICAGO , July 29, 2015  AmnioChor Inc., ... cell technology, is very pleased to announce that the ... has agreed to invest in their seed round ... OmniBank placental tissue storage capabilities. AmnioChor,s ... placenta, and the human stem cells living within those ...
(Date:7/29/2015)... July 29, 2015  Indivior PLC (LON: INDV) today ... nasal spray was accepted and received Priority Review by ... treatment of opioid overdose. This naloxone nasal spray comes ... for optimal absorption into the nasal mucosa. 1 ... so individuals may be better equipped to help an ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5
... Wright, Co-Chair of the Alliance for Biosecurity and ... before the House Labor, Health and Human Services, ... of developing drugs, vaccines and other medical countermeasures ... catastrophic health emergencies. Effective medical countermeasures for many ...
... to Better Serve Asia-Pacific Clinical Trial Enrollment ConcernsNEWTON, ... leader in patient recruitment for clinical trials, has ... G.K., in Osaka, Japan. The company will be ... device companies, as well as CROs and SMOs, ...
... Sopherion Therapeutics, LLC, a biopharmaceutical company focused ... announced that it completed enrollment in its pivotal ... in metastatic HER-2-overexpressing breast cancer. This is ... product in combination with the current standard of ...
Cached Biology Technology:Alliance for Biosecurity Testifies Before Congress on Funding for Medical Countermeasure Development 2Forward-Thinking Patient Recruitment Company Poised to Create Bridges Between Japanese Clinical R&D Industry and Global Clinical Trial Marketplace 2Forward-Thinking Patient Recruitment Company Poised to Create Bridges Between Japanese Clinical R&D Industry and Global Clinical Trial Marketplace 3Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer 2Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer 3
Human MFRP MAb (Clone 291218)...
Human RELT/TNFRSF19L MAb (Clone 238104)...
...
... assay kit measures NOS activity by monitoring ... This assay is simple, sensitive, and specific ... with both crude and purified enzyme preparations. ... for 50 total reactions. Radiolabeled arginine and ...
Biology Products: